Drug Trial Radar · NCT06537414
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
283
Actual
Start
Nov 11, 2024
Primary completion
May 31, 2027
Study completion May 17, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen. The study will also include an optional long-term follow-up (LTFU) extension stage for eligible participants.
Conditions
- Chronic Hepatitis B Virus Infection
- Hepatitis B
Interventions
Daplusiran/Tomligisiran Dose Level 1Drug
Daplusiran/Tomligisiran dose level 1 will be administered
Daplusiran/Tomligisiran Dose Level 2Drug
Daplusiran/Tomligisiran dose level 2 will be administered
BepirovirsenDrug
Bepirovirsen will be administered
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants achieving functional cureTime frame: Up to 100 Weeks
Locations
80 sites in 19 countries. Site status is shown where the registry gives one.
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
New York, New York
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Westmead, New South Wales, Australia
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Ghent, Oost-Vlaanderen, Belgium
GSK Investigational Site
Aracaju, Brazil
GSK Investigational Site
Curitiba, Brazil
GSK Investigational Site
Manaus, Brazil
GSK Investigational Site
São Paulo, Brazil
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Beijing, China
GSK Investigational Site
Chengdu, China
GSK Investigational Site
Guangzhou, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Clichy, France
GSK Investigational Site
Créteil, France
GSK Investigational Site
Limoges, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Marseille, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Münster, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Athens, Greece
GSK Investigational Site
Pokfulam, Hong Kong
GSK Investigational Site
Shatin, Hong Kong
GSK Investigational Site
Bergamo, Italy
GSK Investigational Site
Florence, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Naples, Italy
GSK Investigational Site
Padova, Italy
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.